RESEARCHER PROFILE
Aditya Bardia
← Back to University of California, Los Angeles
A
University of California, Los Angeles
Aditya Bardia works in Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, BRCA gene mutations in cancer. Recorded institutional associations include Harvard University, University of California, Los Angeles, Universidade de São Paulo.
1,252Publications
41,023Citations
90H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 · 2,469 citationsCirculating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
2014 · 2,441 citationsClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
2020 · 1,725 citationsSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2021 · 1,688 citationsInertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
2013 · 1,086 citationsRibociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
2018 · 1,016 citationsOverall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
2019 · 998 citationsPathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
2020 · 938 citationsEx vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
2014 · 913 citationsSacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
2019 · 869 citationsElacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
2022 · 757 citationsA microfluidic device for label-free, physical capture of circulating tumor cell clusters
2015 · 709 citationsChemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
2018 · 530 citationsMalignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
2007 · 503 citationsOverall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 · 488 citationsTrastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 · 485 citationsCyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
2020 · 468 citationsIntercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells
2021 · 418 citationsESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
2021 · 414 citationsEfficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
2017 · 412 citationsAberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
2019 · 408 citationsHER2 expression identifies dynamic functional states within circulating breast cancer cells
2016 · 406 citationsRibociclib plus Endocrine Therapy in Early Breast Cancer
2024 · 405 citationsSacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
2021 · 400 citationsNeoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
2016 · 394 citations
